Publications

Deep TLR Primed™ T cells induce potent anti-tumor activity without systemic toxicity.
Westcott N, Boesch A, Rybakin V, Hwang JY, Jørgensen K, Lassen R, Kraemer M, Bak M, Veiga G, Bruun J, Tassa C, Rodts H, Sequeira M, Sauer K, Andresen, TL. Deep TLR Primed™ T cells induce potent anti-tumor activity without systemic toxicity. American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, November 17–20, 2019.
Download
Combining Deep IL-12 Primed™ and Deep IL-15 Primed™ T cells induces potent antigen-dependent in vitro cytotoxicity and in vivo anti-tumor activity.
Geretti E, Sackton K, Cao P, Carey S, Liang X, Nardozzi J, Gui Z, Worthylake A, Hewes B, Maniar T, Fitzgerald J, Rakestraw A, Jones D, Sauer K, Andresen T. Combining Deep IL-12 Primed™ and Deep IL-15 Primed™ T cells induces potent antigen-dependent in vitro cytotoxicity and in vivo anti-tumor activity. American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, November 17–20, 2019.
Download
Adoptive transfer of deep primed™ IL-12 T-cells increases sensitivity to PD-L1 blockade for superior efficacy in checkpoint refractory tumors.
Ahmad G, Nardozzi J, Ringgaard L, Christensen E, Jaegher D, Suchy J, Karsten Sauer, Douglas Jones, Andresen T. Adoptive transfer of deep primed™ IL-12 T-cells increases sensitivity to PD-L1 blockade for superior efficacy in checkpoint refractory tumors. Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, November 6–10, 2019.
Download
Combining Deep™ IL-12 Primed and Deep™ IL-15 Primed T cells leverages complementary mechanisms to enhance anti-tumor activity.
Sackton K, Geretti E, Cao P, Carey S, Liang X, Nardozzi J, Gui Z, Worthylake A, Leary G, Hewes B, Maniar T, Fitzgerald J, Rakestraw A, Sauer S, Jones D, Andresen T. Combining Deep™ IL-12 Primed and Deep™ IL-15 Primed T cells leverages complementary mechanisms to enhance anti-tumor activity. Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, November 6–10, 2019.
Download
Delivery of TLR7 agonists by Deep-Primed™ T cells induces immune activation and improves anti-tumor activity in mice while circumventing systemic toxicity.
Boesch A, Rybakin V, Westcott N, Hwang JY, Jørgensen K, Lassen R, Kraemer M, Bak M, Veiga G, Bruun J, Tassa C, Rodts H, Sequeira M, Leary G, Caruso S, Hewes B, Fitzgerald J, Sauer K, Andresen T. Delivery of TLR7 agonists by Deep-Primed™ T cells induces immune activation and improves anti-tumor activity in mice while circumventing systemic toxicity. Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, November 6–10, 2019.
Download
Optimized process for manufacturing Deep-Primed™ T cells creates product with improved functional characteristics and reactivity against multiple tumor-associated antigens.
Carey SP, McInnis CM, Worthylake A, Forte A, Brown E, Smith D, Sackton K, Soucy R, Maniar T, Sauer K, Rakestraw A, Andresen T. Optimized process for manufacturing Deep-Primed™ T cells creates product with improved functional characteristics and reactivity against multiple tumor-associated antigens. Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, November 6–10, 2019.
Download
Deep IL-15 primed T cells synergize with PD-L1 blockade to overcome resistance to checkpoint immunotherapy.
Geretti E, Liang X, Lyons J, Bardwell P, Caruso S, Hewes B, Fitzgerald J, Sauer K, Andresen T. Deep IL-15 primed T cells synergize with PD-L1 blockade to overcome resistance to checkpoint immunotherapy. AACR Annual Meeting 2019, April 1, 2019.
Download
Surface-tethered IL-12 improves tumor-specific T-cell therapy and enhances inflammatory activity in tumors without inducing systemic toxicities.
Chang D-K, Ahmad G, Nardozzi J, Sackton K, Lyons J, Sauer K, Andresen T, Jones D. Surface-tethered IL-12 improves tumor-specific T-cell therapy and enhances inflammatory activity in tumors without inducing systemic toxicities. AACR Annual Meeting 2019, March 31, 2019.
Download
Deep™ IL-15 Primed multi-targeted T cells demonstrate potent antigen-specific cytotoxic activity against human cancer cells.
Carey SP, Pearce B, Smith D, Cao P, McInnis C, Shaw A, Bruun J, Fachin F, Hewes B, Fitzgerald JB, Andresen TL, Rakestraw A. Deep™ IL-15 Primed multi-targeted T cells demonstrate potent antigen-specific cytotoxic activity against human cancer cells. Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting, November 7–11, 2018.
Download
Tethering IL-12 to the surface of T cells induces broad immune activation and potent anti-tumor activity in mice without inducing systemic toxicities.
Chang D-K, Ahmad G, Nardozzi JD, Sackton KL, Andresen TL, Jones DS. Tethering IL-12 to the surface of T cells induces broad immune activation and potent anti-tumor activity in mice without inducing systemic toxicities. Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting, November 7–11, 2018.
Download
Preclinical evaluation of Deep™ IL-15 Primed PMEL cells demonstrates highly improved safety compared to systemic administration of IL-15.
Bardwell PD, Geretti E, Liang X, Caruso S, Chang D-K, Lyons J, Tassa C, Bilic S, Lansita J, Hewes B, Fitzgerald J, Andresen TL. Preclinical evaluation of Deep™ IL-15 Primed PMEL cells demonstrates highly improved safety compared to systemic administration of IL-15. Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting, November 7–11, 2018.
Download
A fully closed, high efficiency manufacturing technology platform for the production of T cell therapies targeting multiple tumor antigens.
McInnis CM, Shaw AM, Carey SP, Bruun J, Klaski R, Cao P, Brown E, Rakestraw A, Hewes B, Fitzgerald J, Andresen TL, Fachin F. A fully closed, high efficiency manufacturing technology platform for the production of T cell therapies targeting multiple tumor antigens. Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting, November 7–11, 2018.
Download
T cell priming with Deep™ IL-15 improves preclinical safety compared to systemic IL-15, and increases in vivo persistence and activity.
Geretti E, Bardwell P, Liang X, Caruso S, Chang D-K, Lyons J, Boesch A, Handler A, Tassa C, Bilic S, Lansita J, Hewes B, Fitzgerald J, Andresen T. T cell priming with Deep™ IL-15 improves preclinical safety compared to systemic IL-15, and increases in vivo persistence and activity. CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, September 30, 2018.
Download
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery.
Tang L, Zheng Y, Melo MB, Mabardi L, Castaño AP, Xie YQ, Li N, Kudchodkar SB, Wong HC, Jeng EK, Maus MV, Irvine, DJ. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat. Biotechnol.(2018) Jul 9. doi: 10.1038/nbt.4181. [Epub ahead of print]
Download
Deep™ IL-15 provides autocrine stimulation and expansion of autologous T cells driven by controlled concentrated release of IL-15.
Cao P, Chang D-K, Rakestraw A, Shaw A, Pucci F, Fachin F, McInnis C, Carey S, Boesch A, Chirgwin D, Tassa C, Handler A, Jones K, Bardwell P, Geretti E, Liang X, Nardozzi J, Jones D, Lyons J, Fitzgerald JB, Hewes B, Nielsen UB, Andresen, TL. Deep™ IL-15 provides autocrine stimulation and expansion of autologous T cells driven by controlled concentrated release of IL-15. AACR Annual Meeting 2018, April 17, 2018.
Download
Cell therapy with surface-tethered IL-12 provides immune system priming and strong anti-tumor activity.
Nardozzi J, Geretti E, Chang D-K, McMillin DW, Lyons J, Nielsen U, Andresen T, Jones D. Cell therapy with surface-tethered IL-12 provides immune system priming and strong anti-tumor activity. AACR Annual Meeting 2018, April 17, 2018.
Download
T cell receptor signaling-responsive single chain IL-12 and IL-15 superagonist nanogel ‘backpacks’ to enhance adoptive cell therapy in solid tumors.
Fichter M, Tang L, Zheng Y, Melo M, Li N, Irvine D. T cell receptor signaling-responsive single chain IL-12 and IL-15 superagonist nanogel ‘backpacks’ to enhance adoptive cell therapy in solid tumors. AACR Annual Meeting 2018, April 17, 2018.
Download
Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells.
Jones RB, Mueller S, Kumari S, Vrbanac V, Genel S, Tager AM, Allen TM, Walker BD, Irvine DJ. Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells. Biomaterials (2016) 117:44-53.
Download
Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles.
Stephan MT, Stephan SB, Bak P, Chen J, Irvine DJ. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials (2012) 33(23):5776-5787.
Download
Therapeutic cell engineering with surface-conjugated synthetic nanoparticles.
Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. (2010). 16(9):1035-1041.
Download